Life Sciences

  • November 17, 2025

    DC Circ. Mulls If Gov't Can Say No To 340B Rebate Program

    The D.C. Circuit is set to decide "who's the decision-maker" in a fight brought by drugmakers over the federal government's efforts to reshape the way they do drug rebates after spending more than an hour and a half Monday morning hearing out all sides.

  • November 17, 2025

    Advocacy Groups Push 9th Circ. To Uphold Fluoride Ruling

    Advocacy groups that convinced a California federal judge to rule that the U.S. Environmental Protection Agency's "optimal" level for fluoride in drinking water is not protective enough for children, told the Ninth Circuit Monday that there's no reason to disturb the decision.

  • November 17, 2025

    B. Braun Unit Inks $38.5M Deal To End FCA Knee Implant Case

    The U.S. Department of Justice on Monday announced a $38.5 million False Claims Act settlement with a subsidiary of German medical device giant B. Braun Melsungen AG resolving accusations it sold a knee replacement implant allegedly known to fail prematurely after surgery.

  • November 17, 2025

    2nd Circ. Questions Experts' Rejection In Tylenol Autism Suits

    A Second Circuit panel on Monday appeared skeptical of a lower-court order that barred every expert witness set to testify for families who allege that patients taking Tylenol while pregnant can cause autism or attention deficit hyperactivity disorder in their children.

  • November 17, 2025

    Medtronic Can't Nix FCA Claims Despite 1st Circ. Precedent

    A Massachusetts federal judge reconsidered reviving Medtronic's bid to defeat claims it violated the False Claims Act in light of new First Circuit precedent on a causation standard, but ruled that a whistleblower's evidence warranted keeping the claims alive for now.

  • November 17, 2025

    Pa. Supreme Court Snapshot: Skill Games Top Nov. Lineup

    The Pennsylvania Supreme Court's November session will tackle the legality of the "Pennsylvania Skill" games that have popped up in gas stations and convenience stores, answering the long-simmering question of whether they should be regulated like slot machines. Here are some of the cases the state supreme court will hear during its three-day session in Harrisburg.

  • November 17, 2025

    Cravath, Goodwin Advise On J&J's $3B Cancer Drug Play

    Cravath-advised Johnson & Johnson said Monday it has agreed to pay $3.05 billion in cash for Goodwin-led Halda Therapeutics, a biotech developing a clinical-stage therapy for prostate cancer.

  • November 17, 2025

    Lupin Drops Trade Secrets Case Against Rival

    Pharmaceutical company Lupin Inc. has agreed to drop allegations of stealing trade secrets against Transpire Bio Inc. and former Lupin employee Xian-Ming Zeng, after two other former Lupin employees escaped the suit last month.

  • November 17, 2025

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court and Delaware Supreme Court last week had a dense slate of fiduciary duty battles, merger-process challenges, post-bankruptcy fights and a series of cases probing the limits of fraud pleading, credible-basis inspections and board-level disclosure duties.

  • November 17, 2025

    3 Firms Advising On CD&R's $10.3B Bubble Wrap Maker Buy

    Private equity firm CD&R has agreed to purchase Sealed Air Corp., a provider of packaging solutions including Bubble Wrap and Cryovac, at an enterprise value of $10.3 billion in a deal steered by three law firms, Sealed Air said in a Monday announcement.

  • November 17, 2025

    No High Court Review For FDA Fast-Track Denial

    The U.S. Supreme Court on Monday said it would not consider whether federal drug regulators went astray in denying fast-track review for a digestive disorder medication being developed by Vanda Pharmaceuticals.

  • November 14, 2025

    Texas Judge Rejects Bid To Block Kenvue's $398M Dividend

    Texas can't stop the makers of Tylenol from marketing the drug as safe for children and pregnant women or halt a nearly $400 million payment to shareholders, a state court ruled on Friday, rejecting arguments by Attorney General Ken Paxton's motion.

  • November 14, 2025

    Amazon Blasts Claim It Destroyed Evidence In Labeling Suit

    Amazon.com Services LLC is fighting calls for sanctions in a proposed class action accusing it of failing to follow federal labeling laws for dietary supplements, saying it shouldn't be penalized for allegedly failing to preserve online product pages for the supplements.

  • November 14, 2025

    Apple Hit By $634M Verdict Over Masimo Health Tech Patent

    A California federal jury on Friday awarded Masimo Corp. more than $634 million from Apple Inc. following an eight-day trial, finding that certain Apple Watches infringed one of Masimo's pulse oximetry patents with a feature that warns users if they have an abnormal heart rate. 

  • November 14, 2025

    ITC To Scrutinize Redesigned Apple Watch In Masimo IP Fight

    The U.S. International Trade Commission said Friday that it would review whether redesigned Apple Watches violate a previous order that briefly blocked imports of the devices deemed to infringe a pair of patents owned by Masimo, which urged the ITC to scrutinize the modified products.

  • November 14, 2025

    Ethiopian Importer Asks Court To Enforce $5M Arbitration Win

    An Ethiopian import company has asked a California federal court to enforce a $5.3 million arbitral award against a medical supply company following a dispute over a botched contract.

  • November 14, 2025

    Drug Buyers Defend Class Cert. In 3rd Circ. Generics Case

    Direct purchasers and end-payers in the sprawling multidistrict litigation over alleged price-fixing of generic drugs are fighting requests from Actavis and Mylan to undo class certification in the cases, arguing to the Third Circuit that the litigation is a classic example of a class action matter.

  • November 14, 2025

    Tricida Trustee Jackson Square Sues Over $740M Loss

    The liquidating trustee for bankrupt drug developer Tricida has filed a complaint in U.S. Bankruptcy Court for the District of Delaware accusing seven former executives and directors, along with an investment firm, of systematically stripping more than $740 million in corporate assets through insider trading, self-approved bonuses and a deliberate failure to protect valuable tax attributes before its 2023 collapse.

  • November 14, 2025

    DOJ Official Among Trump Picks For District Courts

    President Donald Trump announced judicial nominees for federal courts in Tennessee, Indiana and Missouri on Friday, including a current U.S. Department of Justice official.

  • November 14, 2025

    DC Circ. Wary Of DEA Delays In Religious Ayahuasca Case

    A D.C. Circuit panel on Friday appeared skeptical that the Drug Enforcement Administration was justified in its delays processing an Iowa church's application for a religious exemption to the Controlled Substances Act to use a psychedelic in its rites.

  • November 14, 2025

    Taxation With Representation: Wachtell, Paul Hastings, Sidley

    In this week's Taxation With Representation, Pfizer Inc. completes its acquisition of obesity drug developer Metsera Inc., motion and controls technologies company Parker-Hannifin Corp. acquires Filtration Group Corp., and fund administrator JTC PLC backs a cash offer in the billions from British private equity shop Permira.

  • November 14, 2025

    Photographer Sues Gilead For Continued Use Of Ad Images

    A photographer sued Gilead Sciences Inc., claiming the pharmaceutical giant had used a set of images he'd taken for an advertisement series long after it knew its license for the photos expired.

  • November 14, 2025

    Purdue's $7.4B Ch. 11 Plan To Be Confirmed

    A New York bankruptcy judge agreed to confirm the $7.4 billion Chapter 11 plan of Purdue Pharma LP on Friday, saying he would issue a formal bench ruling next Tuesday explaining his decision.

  • November 14, 2025

    Gibson Dunn, Cooley Guide Merck's $9.2B Cidara Buy

    Gibson Dunn & Crutcher LLP-advised Merck on Friday said it will broaden its respiratory portfolio with a $9.2 billion deal to buy Cooley LLP-led Cidara Therapeutics, betting that an investigational antiviral could help the company tackle the global health burden of seasonal influenza.

  • November 13, 2025

    J&J Bellwether Trial Over Talc Cancer Risks Kicks Off In LA

    An attorney for one of two women who claim Johnson & Johnson's talcum products caused their ovarian cancer told a Los Angeles jury Thursday during opening statements in a bellwether trial that decades-old internal documents prove J&J knew its talc products contained toxic levels of asbestos but hid that information.

Expert Analysis

  • Lessons From 7th Circ. Decision Affirming $183M FCA Verdict

    Author Photo

    The Seventh Circuit's decision to uphold a $183 million False Claims Act award against Eli Lilly engages substantively with recurring materiality and scienter questions and provides insights into appellate review of complex trial court judgments, say Ellen London at London & Naor, Li Yu at Bernstein Litowitz and Kimberly Friday at Osborn Maledon.

  • Opinion

    Punitive Damages Awards Should Be Limited To 1st Instance

    Author Photo

    Recent verdicts in different cases against Johnson & Johnson and Monsanto showcase a trend of multiple punitive damages being awarded to different plaintiffs for the same course of conduct by a single defendant, a practice that should be deemed unconstitutional by the U.S. Supreme Court, says Jacob Mihm at Polales Horton.

  • How Calif. High Court Is Rethinking Forum Selection Clauses

    Author Photo

    Two recent cases before the California Supreme Court show that the state is shifting toward greater enforcement of freely negotiated forum selection clauses between sophisticated parties, so litigators need to revisit old assumptions about the breadth of California's public policy exception, says Josh Patashnik at Perkins Coie.

  • AI Litigation Tools Can Enhance Case Assessment, Strategy

    Author Photo

    Civil litigators can use artificial intelligence tools to strengthen case assessment and aid in early strategy development, as long as they address the risks and ethical considerations that accompany these uses, say attorneys at Barnes & Thornburg.

  • Attys Beware: Generative AI Can Also Hallucinate Metadata

    Author Photo

    In addition to the well-known problem of AI-generated hallucinations in legal documents, AI tools can also hallucinate metadata — threatening the integrity of discovery, the reliability of evidence and the ability to definitively identify the provenance of electronic documents, say attorneys at Law & Forensics.

  • Lessons From Fed. Circ. On Expert Testimony In Patent Cases

    Author Photo

    Several recent decisions from the Federal Circuit are notable for their treatment of expert testimony, with relevance to the three pillars of every patent case — infringement, invalidity and damages — and offer lessons on ensuring that expert testimony is both admissible and sufficient to support the jury's verdict, say attorneys at Honigman.

  • When Atty Ethics Violations Give Rise To Causes Of Action

    Author Photo

    Though the Model Rules of Professional Conduct make clear that a violation of the rules does not automatically create a cause of action, attorneys should beware of a few scenarios in which they could face lawsuits for ethical lapses, says Brian Faughnan at Faughnan Law.

  • What's New In FDA's Latest Cell And Gene Therapy Guidance

    Author Photo

    New draft guidance from the U.S. Food and Drug Administration, along with other recent initiatives, come together to promote cell and gene therapy product development by streamlining development and review pathways, say attorneys at Holland & Knight.

  • Trending At The PTAB: A Potential Barrier To Serial Challenges

    Author Photo

    New rules proposed by the U.S. Patent and Trademark Office may appear similar to previous rules at first glance, but are actually much broader in how they would limit petitioners' ability to challenge a patent more than once, say attorneys at Finnegan.

  • What's Changing For Cos. In New Calif. Hazardous Waste Plan

    Author Photo

    While the latest hazardous waste management plan from California's Department of Toxic Substances Control still awaits final approval, companies can begin aligning internal systems now with the plan's new requirements for environmental justice, waste and disposal reduction, waste criteria, and capacity planning, says Thierry Montoya at Frost Brown.

  • Fed. Circ. In September: The Printed Matter Doctrine Expands

    Author Photo

    The Federal Circuit’s recent decision in Bayer v. Mylan represents an extension of the doctrine that adding new words to an existing product or method will not support patentability unless there is a functional relationship, bringing new considerations for both patent holders and challengers, say attorneys at Knobbe Martens.

  • Justices' LabCorp Punt Leaves Deeper Class Cert. Circuit Split

    Author Photo

    In its ruling in LabCorp v. Davis, the U.S. Supreme Court left unresolved a standing-related class certification issue that has plagued class action jurisprudence for years — and subsequent conflicting decisions among federal circuit courts have left district courts and litigants struggling with conflicting and uncertain standards, say attorneys at Cozen O'Connor.

  • Series

    Practicing Stoicism Makes Me A Better Lawyer

    Author Photo

    Practicing Stoicism, by applying reason to ignore my emotions and govern my decisions, has enabled me to approach challenging situations in a structured way, ultimately providing advice singularly devoted to a client's interest, says John Baranello at Moses & Singer.

  • Broader Eligibility For AI-Related Patents May Be Coming

    Author Photo

    A series of recent developments from the U.S. Patent and Trademark Office appears to signal that claims involving improvement in the operation of a machine learning model are now more likely to be considered patent-eligible, and that patent examiners may focus on questions of novelty and nonobviousness and less so on subject matter eligibility, say attorneys at Kilpatrick.

  • Series

    The Biz Court Digest: Texas, One Year In

    Author Photo

    A year after the Texas Business Court's first decision, it's clear that Texas didn't just copy Delaware and instead built something uniquely its own, combining specialization with constitutional accountability and creating a model that looks forward without losing touch with the state's democratic and statutory roots, says Chris Bankler at Jackson Walker.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.